Maurie Markman1, Jerome Belinson. 1. Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA. mmarkman@mdanderson.org
Abstract
PURPOSE: Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined. METHODS: Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program. Following major objective and subjective responses each patient underwent a surgical re-assessment and subsequently received single-agent intraperitoneal platinum (cisplatin or carboplatin). RESULTS AND CONCLUSION: In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.
PURPOSE: Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined. METHODS: Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program. Following major objective and subjective responses each patient underwent a surgical re-assessment and subsequently received single-agent intraperitoneal platinum (cisplatin or carboplatin). RESULTS AND CONCLUSION: In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.
Authors: Richard R Barakat; Paul Sabbatini; Dharmendra Bhaskaran; Margarita Revzin; Alex Smith; Ennapadam Venkatraman; Carol Aghajanian; Martee Hensley; Steven Soignet; Carol Brown; Robert Soslow; Maurie Markman; William J Hoskins; David Spriggs Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Y Ansquer; E Leblanc; K Clough; P Morice; J Dauplat; P Mathevet; C Lhommé; C Scherer; J D Tigaud; M Benchaib; E Fourme; D Castaigne; D Querleu; D Dargent Journal: Cancer Date: 2001-06-15 Impact factor: 6.860
Authors: W Kuhn; S Rutke; K Späthe; B Schmalfeldt; G Florack; B von Hundelshausen; D Pachyn; K Ulm; H Graeff Journal: Cancer Date: 2001-11-15 Impact factor: 6.860
Authors: F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333
Authors: M Markman; B Reichman; T Hakes; J L Lewis; W Jones; S Rubin; R Barakat; J Curtin; L Almadrones; W Hoskins Journal: J Clin Oncol Date: 1992-09 Impact factor: 44.544
Authors: F C Muñoz-Casares; S Rufián; M J Rubio; E Lizárraga; C Díaz-Iglesias; E Aranda; R Ciria; J Muntané; P Barrios; J Torres-Melero; S González-Moreno; L González-Bayón; B Camps; P Bretcha; J Farré; G Ortega-Pérez; A Gómez-Portilla Journal: Clin Transl Oncol Date: 2007-10 Impact factor: 3.405